Skip to main content

Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage.

Publication ,  Journal Article
Pan, G; Roy, B; Harding, P; Lanigan, T; Hilgarth, R; Thandavarayan, RA; Palaniyandi, SS
Published in: Gene therapy
February 2023

Intrinsic activity of aldehyde dehydrogenase (ALDH)2, a cardiac mitochondrial enzyme, is vital in detoxifying 4-hydroxy-2-nonenal (4HNE) like cellular reactive carbonyl species (RCS) and thereby conferring cardiac protection against pathological stress. It was also known that a single point mutation (E487K) in ALDH2 (prevalent in East Asians) known as ALDH2*2 reduces its activity intrinsically and was associated with increased cardiovascular diseases. We and others have shown that ALDH2 activity is reduced in several pathologies in WT animals as well. Thus, exogenous augmentation of ALDH2 activity is a good strategy to protect the myocardium from pathologies. In this study, we will test the efficacy of intracardiac injections of the ALDH2 gene in mice. We injected both wild type (WT) and ALDH2*2 knock-in mutant mice with ALDH2 constructs, AAv9-cTNT-hALDH2-HA tag-P2A-eGFP or their control constructs, AAv9-cTNT-eGFP. We found that intracardiac ALDH2 gene transfer increased myocardial levels of ALDH2 compared to GFP alone after 1 and 3 weeks. When we subjected the hearts of these mice to 30 min global ischemia and 90 min reperfusion (I-R) using the Langendorff perfusion system, we found reduced infarct size in the hearts of mice with ALDH2 gene vs GFP alone. A single time injection has shown increased myocardial ALDH2 activity for at least 3 weeks and reduced myocardial 4HNE adducts and infarct size along with increased contractile function of the hearts while subjected to I-R. Thus, ALDH2 overexpression protected the myocardium from I-R injury by reducing 4HNE protein adducts implicating increased 4HNE detoxification by ALDH2. In conclusion, intracardiac ALDH2 gene transfer is an effective strategy to protect the myocardium from pathological insults.

Duke Scholars

Published In

Gene therapy

DOI

EISSN

1476-5462

ISSN

0969-7128

Publication Date

February 2023

Volume

30

Issue

1-2

Start / End Page

115 / 121

Related Subject Headings

  • Point Mutation
  • Myocardium
  • Mitochondria
  • Mice
  • Infarction
  • Biotechnology
  • Animals
  • Aldehyde Dehydrogenase, Mitochondrial
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pan, G., Roy, B., Harding, P., Lanigan, T., Hilgarth, R., Thandavarayan, R. A., & Palaniyandi, S. S. (2023). Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage. Gene Therapy, 30(1–2), 115–121. https://doi.org/10.1038/s41434-022-00345-2
Pan, Guodong, Bipradas Roy, Pamela Harding, Thomas Lanigan, Roland Hilgarth, Rajarajan A. Thandavarayan, and Suresh Selvaraj Palaniyandi. “Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage.Gene Therapy 30, no. 1–2 (February 2023): 115–21. https://doi.org/10.1038/s41434-022-00345-2.
Pan G, Roy B, Harding P, Lanigan T, Hilgarth R, Thandavarayan RA, et al. Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage. Gene therapy. 2023 Feb;30(1–2):115–21.
Pan, Guodong, et al. “Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage.Gene Therapy, vol. 30, no. 1–2, Feb. 2023, pp. 115–21. Epmc, doi:10.1038/s41434-022-00345-2.
Pan G, Roy B, Harding P, Lanigan T, Hilgarth R, Thandavarayan RA, Palaniyandi SS. Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage. Gene therapy. 2023 Feb;30(1–2):115–121.

Published In

Gene therapy

DOI

EISSN

1476-5462

ISSN

0969-7128

Publication Date

February 2023

Volume

30

Issue

1-2

Start / End Page

115 / 121

Related Subject Headings

  • Point Mutation
  • Myocardium
  • Mitochondria
  • Mice
  • Infarction
  • Biotechnology
  • Animals
  • Aldehyde Dehydrogenase, Mitochondrial
  • 42 Health sciences
  • 32 Biomedical and clinical sciences